Nanoparticle In Vivo Reagent

Catalog # 5030 - 0.5 mL (10 injections)	$ 445
Catalog # 5031 - 1.5 mL (30 injections)	$ 955

In Vivo Transfection Reagent (Nanoparticle-based)

Reagent optimized and validated for siRNA and plasmid DNA in vivo delivery

Modes of administration:

• Systemic intravenous (i.v.) injection
• Direct intratumoral (i.t.) injection

Altogen's In Vivo Transfection Reagent

• Forms siRNA-nanoparticle and DNA-nanoparticle complexes
• Complexes are stable in serum for 16h
• Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration
• Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (various tumor types)
• Minimal toxicity 
• Functionally tested in mice
• Applicable for plasmid DNA/siRNA co-injection
• Transfection protocols are provided with the purchase of the reagent
• Developed and manufactured by Altogen Biosystems

Data

Figure 1. Systemic administration (i.v.) of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 2. Intratumoral administration (i.t.) of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

*Reagent can be purchased by PO or Credit Card by adding product to the Shopping Cart.